Published in Transplant Proc on February 01, 1993
Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev (2010) 3.31
Into the eye of the cytokine storm. Microbiol Mol Biol Rev (2012) 2.58
IL-17 contributes to CD4-mediated graft-versus-host disease. Blood (2008) 2.07
Principles of bone marrow transplantation (BMT): providing optimal veterinary and husbandry care to irradiated mice in BMT studies. J Am Assoc Lab Anim Sci (2009) 1.39
Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech (2011) 1.16
New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol (2015) 1.10
Serum cytokines in a clinical trial of hypothermia for neonatal hypoxic-ischemic encephalopathy. J Cereb Blood Flow Metab (2012) 1.05
Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD. Autophagy (2010) 1.04
The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med (2013) 1.00
Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Support Care Cancer (2008) 0.91
Nuclear receptors in inflammation control: repression by GR and beyond. Mol Cell Endocrinol (2013) 0.90
Agents to reduce cytokine storm. F1000Res (2016) 0.75
Cytokine Detection and Modulation in Acute Graft vs. Host Disease in Mice. Mediators Inflamm (1994) 0.75
Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation. Oncotarget (2016) 0.75
Miniature Swine as a Clinically Relevant Model of Graft-Versus-Host Disease. Comp Med (2015) 0.75
Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol (2017) 0.75
[Pathogenesis and morphology of hemophagocytic syndrome in the spleen]. Pathologe (2008) 0.75
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet (1999) 6.61
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 4.64
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med (1994) 4.46
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (1995) 3.38
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia (2009) 3.23
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood (1996) 2.73
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia (2010) 2.65
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia (2007) 2.49
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell (2000) 2.41
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J (1997) 2.06
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A (1996) 1.98
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol (1996) 1.93
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer (1997) 1.82
The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol (1996) 1.75
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol (2005) 1.56
The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev (1998) 1.55
Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood (1998) 1.55
Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci U S A (1980) 1.54
Hematologic malignancies. Curr Opin Hematol (2001) 1.52
Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J (2000) 1.44
Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol (2001) 1.41
ARG tyrosine kinase activity is inhibited by STI571. Blood (2001) 1.35
Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant (2007) 1.34
TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood (1996) 1.33
Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood (1998) 1.31
Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol (2001) 1.28
Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia (2004) 1.21
Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J Clin Invest (2000) 1.21
X-inactivation analysis in the 1990s: promise and potential problems. Leukemia (1998) 1.20
TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood (1999) 1.19
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene (1996) 1.19
Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia (2002) 1.18
PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia (2009) 1.16
An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X. Nucleic Acids Res (1994) 1.15
Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene (2000) 1.14
Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia (2008) 1.14
Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood (1991) 1.14
Chimeric toxins: toxic, disulfide-linked conjugate of concanavalin A with fragment A from diphtheria toxin. Proc Natl Acad Sci U S A (1978) 1.13
Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell (1980) 1.13
Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood (1996) 1.08
Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant (1997) 1.08
The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet Cytogenet (2001) 1.08
The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood (2001) 1.06
Serotype c Streptococcus mutans mutatable to lactate dehydrogenase deficiency. J Dent Res (1985) 1.05
Molecular biology of acute myeloid leukemia. Semin Oncol (1997) 1.04
TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood (1995) 1.04
The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol (1997) 1.03
Clonal evolution in acute myeloid leukemia. Blood (1993) 1.03
Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood (1994) 1.00
Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia (2008) 1.00
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia (2008) 0.99
Transforming properties of the Huntingtin interacting protein 1/ platelet-derived growth factor beta receptor fusion protein. J Biol Chem (1999) 0.99
Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission. Int J Hematol (2010) 0.96
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol (2004) 0.96
Engraftment following T cell-depleted bone marrow transplantation. III. Differential effects of increased total-body irradiation on semiallogeneic and allogeneic recipients. Transplantation (1988) 0.96
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood (2001) 0.94
Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation (1993) 0.94
Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol (1996) 0.92
Natural killer cell lymphoproliferative disease associated with neuropathy. Am J Med (1995) 0.90
TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia. Leukemia (1997) 0.90
TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol (2000) 0.88
Late-onset intestinal perforation in the setting of posttransplantation microangiopathy: a case report. Transplant Proc (2010) 0.86
Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J (2011) 0.86
EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia (2011) 0.85
The TEL gene and human leukemia. Biochim Biophys Acta (1996) 0.84
Lymphocytes with a CD4+ CD8- CD3- phenotype are effectors of experimental cutaneous graft-versus-host disease. Proc Natl Acad Sci U S A (1991) 0.84
Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2009) 0.84
CBFA2, frequently rearranged in leukemia, is not responsible for a familial leukemia syndrome. Leukemia (1997) 0.83
Myelodysplastic syndrome. Curr Opin Hematol (1995) 0.82
Cariogenicity of a lactate dehydrogenase-deficient mutant of Streptococcus mutans serotype c in gnotobiotic rats. Infect Immun (1989) 0.81
Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus. J Clin Endocrinol Metab (1994) 0.81
Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach. Transpl Infect Dis (2010) 0.81
Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood (1998) 0.81
Evaluation of the half-life of intravenous human cytomegalovirus immune globulin in patients receiving partially mismatched related donor bone marrow transplantation. Pharmacotherapy (2000) 0.80
Flow cytometric cell sorting combined with molecular chimerism analysis to detect minimal recurrent leukemia: good news and bad news. Bone Marrow Transplant (1997) 0.79
Analysis of meningiomas by methylation- and transcription-based clonality assays. Cancer Res (1995) 0.79
Partially mismatched related donor transplants as salvage therapy for patients with refractory leukemia who relapse post-BMT. Bone Marrow Transplant (1996) 0.78
Clonality in juvenile chronic myelogenous leukemia. Blood (1995) 0.78
BU, melphalan and thiotepa as a preparative regimen for auto-transplantation in Hodgkin's disease. Bone Marrow Transplant (2011) 0.78
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study. Cytotherapy (2003) 0.78
Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol (1993) 0.78
Clonality analysis of childhood ALL in remission: no evidence of clonal hematopoiesis. Leuk Res (1994) 0.77
Translocation (2;8)(p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/AML1 gene rearrangement in a child with acute lymphoblastic leukemia. Cancer Genet Cytogenet (2000) 0.77
Newborn screening for sickle cell disease. When is an infant 'lost to follow-up'? Am J Dis Child (1990) 0.77
SENCAR mouse skin tumors produced by promotion alone have A to G mutations in codon 61 of the c-rasHa gene. Carcinogenesis (1994) 0.77
Structure-activity relationships in diphtheria toxin and exotoxin A from Pseudomonas aeruginosa. Prog Clin Biol Res (1979) 0.77
Clonality in myeloproliferative disorders. Am J Med Sci (1992) 0.77
Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Am J Hematol (1997) 0.77